| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/26/2002 | US6350855 Human interleukin-11 receptor |
| 02/26/2002 | US6350782 Use of basic amino acids derivatives for lowering ceramide levels |
| 02/26/2002 | US6350774 Antithrombotic agents |
| 02/26/2002 | US6350767 Growth hormone release stimulant |
| 02/26/2002 | US6350764 Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors |
| 02/26/2002 | US6350761 Benzenamine derivatives as anti-coagulants |
| 02/26/2002 | US6350759 Dihydro- and tetrahydro-quinoline compounds |
| 02/26/2002 | US6350758 Tropane derivatives and method for their synthesis |
| 02/26/2002 | US6350750 Quinoline and quinazoline derivatives having corticotropin releasing factor (CRF) antagonist activity |
| 02/26/2002 | US6350747 Protein serine/threonine kinase and protein tyrosine kinase enzyme inhibitors; angiogenesis inhibitors; antitumor and antiproliferative agents |
| 02/26/2002 | US6350745 Thrombin inhibitors |
| 02/26/2002 | US6350741 Inhibitors of interleukin-1β converting enzyme |
| 02/26/2002 | US6350603 Phosphodiesterase 10 |
| 02/26/2002 | US6350598 MurD |
| 02/26/2002 | US6350593 Receptors for fibroblast growth factors |
| 02/26/2002 | US6350479 Treating depression with alcohol extracts of tobacco |
| 02/26/2002 | US6350446 Polypeptides with amino acid sequences for kidney failure |
| 02/26/2002 | CA2211727C Large area submucosal graft constructs and method for making the same |
| 02/26/2002 | CA2178302C Indole, indazole and benzisoxazole derivatives; process for preparing the same and pharmaceutical compositions containing them |
| 02/26/2002 | CA2163535C Inhibition of hair growth |
| 02/26/2002 | CA2160966C Piperidine derivatives; process for preparing them and compositions containing the same |
| 02/26/2002 | CA2128119C Benzospiroalkene derivatives, process for their preparation and pharmaceutical compositions containing them |
| 02/26/2002 | CA2078875C High level expression of basic fibroblast growth factor having a homogeneous n-terminus |
| 02/26/2002 | CA2063550C Azomethines agonist compounds of the histamine h3 receptor for therapeutic use, pharmaceutical compositions acting as agonists of said receptor and method of preparation |
| 02/26/2002 | CA2024672C Indole, benzofuran,and benzothiophene containing lipoxygenase inhibiting compounds |
| 02/21/2002 | WO2002014554A2 The anti-neoplastic agent et-743 inhibits trans activation by sxr |
| 02/21/2002 | WO2002014536A2 Odulating multiple lineage kinase proteins |
| 02/21/2002 | WO2002014513A1 Use of polypeptide |
| 02/21/2002 | WO2002014511A2 Regulation of human p2y1-like g protein-coupled receptor |
| 02/21/2002 | WO2002014499A2 Claudin polypeptides |
| 02/21/2002 | WO2002014487A2 Adeno-associated virus-mediated delivery of angiogenic factors |
| 02/21/2002 | WO2002014477A2 Bioavailable composition of natural and synthetic hca |
| 02/21/2002 | WO2002014470A2 Expression of herstatin, an alternative her-2/neu product, in cells that express either p185her-2 or the egf receptor inhibits receptor activity and cell growth |
| 02/21/2002 | WO2002014369A2 Human kininogen d5 domain polypeptides and their use |
| 02/21/2002 | WO2002014357A2 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 02/21/2002 | WO2002014349A2 Non-covalent inhibitors of urokinase and blood vessel formation |
| 02/21/2002 | WO2002014342A1 Steroid derived antibiotics |
| 02/21/2002 | WO2002014319A2 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 02/21/2002 | WO2002014315A2 Substituted pyrazoles |
| 02/21/2002 | WO2002014314A2 Substituted pyrazoles |
| 02/21/2002 | WO2002014313A2 Novel beta-amyloid inhibitors, method for producing the same and the use thereof as medicaments |
| 02/21/2002 | WO2002014311A2 Urea compounds and methods of uses |
| 02/21/2002 | WO2002014310A1 2-[5-AMINO-6-OXO-2-PHENYL-1,6-DIHYDRO-1-PYRIMIDYL]-N-[1-(2-[5-t-BUTYL-1,3,4-OXADIAZOLYL]CARBONYL)-2-(R,S)-METHYLPROPYL]ACETAMIDE HYDROCHLORIDE |
| 02/21/2002 | WO2002014294A2 Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function |
| 02/21/2002 | WO2002014291A1 PPARδ ACTIVATORS |
| 02/21/2002 | WO2002014285A1 Substituted imidazoles as tafia inhibitors |
| 02/21/2002 | WO2002014282A1 2-aminopyridine compounds and use thereof as drugs |
| 02/21/2002 | WO2002014281A1 Pyridine derivatives as inhibitors of p38 |
| 02/21/2002 | WO2002014275A2 Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function |
| 02/21/2002 | WO2002014274A1 Selective urokinase inhibitors |
| 02/21/2002 | WO2002014272A1 (thio)urea derivatives, process for their production and medicines containing the derivatives |
| 02/21/2002 | WO2002014271A1 Proline derivatives and use thereof as drugs |
| 02/21/2002 | WO2002014270A1 New amidino derivatives and their use as thrombin inhibitors |
| 02/21/2002 | WO2002014269A2 2,4-substituted pyridine derivatives |
| 02/21/2002 | WO2002014262A1 2,3-diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage |
| 02/21/2002 | WO2002013872A1 Peptide and peptide mimetic conjugates with integrin-inhibitor properties |
| 02/21/2002 | WO2002013846A2 Antifungal combination therapy |
| 02/21/2002 | WO2002013845A2 Inflammation related g-protein coupled receptor |
| 02/21/2002 | WO2002013828A1 A retroviral immunotherapy |
| 02/21/2002 | WO2002013827A1 Process for the preparation of dinapsoline |
| 02/21/2002 | WO2002013824A1 Cyclopentyl modulators of chemokine receptor activity |
| 02/21/2002 | WO2002013821A1 Novel alicyclic imidazoles as h3 agents |
| 02/21/2002 | WO2002013810A1 Water-soluble prodrugs of propofol for treatment of migraine |
| 02/21/2002 | WO2002013808A2 Treatment of tumors with acetylenes distributed with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| 02/21/2002 | WO2002013802A2 Method of treating estrogen receptor positive carcinoma |
| 02/21/2002 | WO2002013798A2 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 02/21/2002 | WO2002013797A2 Therapeutic combination of a cetp inhibitor and atorvastatin |
| 02/21/2002 | WO2002013788A1 Topical aminolevulinic acid-photodynamic therapy for acne vulgaris |
| 02/21/2002 | WO2002013758A2 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | WO2001090063A3 Prodrug of an ice inhibitor |
| 02/21/2002 | WO2001085668A8 Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them |
| 02/21/2002 | WO2001085256A3 Critical illness neuropathy |
| 02/21/2002 | WO2001083698A3 Compositions and methods for inducing activation of dendritic cells |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001076601A3 Pharmaceutical compositions comprising salmeterol and ipratropium |
| 02/21/2002 | WO2001074313A3 Compositions and methods for treating hair loss using c16 - c20 aromatic tetrahydro prostaglandins |
| 02/21/2002 | WO2001074295A3 Phospholipid scramblases and methods of use thereof |
| 02/21/2002 | WO2001072960A3 Il-8 receptor antagonists |
| 02/21/2002 | WO2001072291A3 Treatment of movement disorders with metabotropic glutamate receptor antagonist |
| 02/21/2002 | WO2001070807A3 G-protein associated molecules |
| 02/21/2002 | WO2001068609B1 1,2,3,4-tetrahydroisoquinoline derivatives |
| 02/21/2002 | WO2001068065A3 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 02/21/2002 | WO2001064240A3 Methods for promoting production of myelin by schwann cells |
| 02/21/2002 | WO2001062901A3 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
| 02/21/2002 | WO2001054711A3 Use of neurotoxins for treating diabetes |
| 02/21/2002 | WO2001049832A3 Transduction of recombinases for inducible gene targeting |
| 02/21/2002 | WO2001049703A3 Substituted sapogenins and their use |
| 02/21/2002 | WO2001047510A3 Methods and compositions related to modulators of annexin and cartilage homeostasis |
| 02/21/2002 | WO2001046397A3 Human kinases |
| 02/21/2002 | WO2001044282A3 Bcl-g polypeptides, encoding nucleic acids and methods of use |
| 02/21/2002 | WO2001032871A3 Follistatin-related protein zfsta4 |
| 02/21/2002 | WO2001032631A3 Heterocyclic cytotoxic agents |
| 02/21/2002 | WO2001026658A3 Topical nasal treatment using desloratadine |
| 02/21/2002 | WO2000066148A9 Novel proteins |
| 02/21/2002 | US20020022729 Pyridylfuran and pyridylthiophene compounds |
| 02/21/2002 | US20020022718 Genes identified as required for proliferation of E. coli |
| 02/21/2002 | US20020022665 Anti-carcinogenic activity of hydroxylated chalcone compounds extracted from licorice root |
| 02/21/2002 | US20020022655 Leukemic cell growth inhibiting method |
| 02/21/2002 | US20020022653 Cannabinoid drugs |
| 02/21/2002 | US20020022648 Novel 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists |